Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a
commercial-stage pharmaceutical company that focuses on the
development and commercialization of pharmaceutical products for
the treatment of dermatological conditions, today announced
financial results and recent corporate highlights for the fourth
quarter and full year ended December 31, 2022.
Claude Maraoui, Journey Medical’s Co-Founder,
President and Chief Executive Officer, said, “Our first year as a
public company had many achievements and challenges, including the
impact of generic competition on our Targadox® brand and supply
chain issues for Ximino® and Exelderm®, which were resolved in
2022. Looking beyond these challenges, and forward into 2023, we
have accomplished a great deal over this past year, particularly
revenue growth for Qbrexza® and Accutane® in addition to the
revenue contribution of Amzeeq® and Zilxi®, acquired in January
2022. These four products accounted for approximately 77% of our
total revenue for the year. In 2023, we look forward to continued
revenue growth from these products and achieving clinical
milestones in our Phase 3 clinical trials evaluating DFD-29 for the
treatment of rosacea. We expect a top-line data read out from the
DFD-29 Phase 3 clinical trials in the second quarter of 2023 and to
file a New Drug Application (“NDA”) in the second half of
2023.”
Financial Results:
- Total revenues were $73.7 million
for the full year 2022, a record high for the Company, compared to
total revenues of $63.1 million for the full year 2021,
representing 17% growth. This includes total revenues of $16.0
million for the fourth quarter of 2022, compared to net revenues of
$17.5 million generated in the fourth quarter of 2021, representing
a 9% decline from period-to-period primarily due to generic
competition for Targadox.
- Selling, general and administrative
expenses were $59.5 million for the full year 2022, compared to
$39.8 million for 2021. The increase is primarily attributable to
the expansion of our salesforce, marketing expenses related to the
expanded product portfolio of four products, additional headcount
costs, legal expenses associated with successful patent litigation
and other professional fees associated with being a public company
that we did not incur as a privately held company prior to our IPO
in November 2021.
- Selling, general and administrative
expenses were $14.0 million for the fourth quarter of 2022,
compared to $15.1 million for the fourth quarter of 2021. The
decrease is primarily attributable to our expense optimization
efforts as the Company continues to improve its operational
efficiencies post IPO, while ensuring continued focus on the
development and commercialization of DFD-29.
- Research and development costs were
$10.9 million for the full year 2022, compared to $16.6 million for
the full year 2021. The full year 2021 included $13.8 million for
the license acquisition of DFD-29.
- Research and development costs were
$4.3 million for the fourth quarter of 2022, compared to $2.0
million for the fourth quarter of 2021 due to clinical trial
expenses related to the development of our DFD-29 product
candidate, for which our Phase 3 clinical trials are 100%
enrolled.
- Net loss was $29.6 million, or
$1.69 per share basic and diluted, for the full year 2022, compared
to net loss of $44.0 million or $4.32 per share basic and diluted
for the full year 2021, reflecting a decrease of $14.4 million from
period-to-period. Net loss was $10.6 million, or $0.60 per share
basic and diluted, for the fourth quarter of 2022, compared to net
loss of $21.8 million or $1.64 per share basic and diluted for the
fourth quarter of 2021, reflecting a decrease of $11.2 million from
period-to-period.
- The Company’s non-GAAP results in
the table below reflect Adjusted EBITDA of $(7.3 million), or
$(0.42) per share basic and diluted, for the full year 2022,
compared to Adjusted EBITDA of $(10.9 million), or $(1.07) per
share basic and diluted for the full year 2021. The Company’s
non-GAAP results in the table below reflect Adjusted EBITDA of
$(3.0 million), or $(0.17) per share basic and diluted, for the
fourth quarter of 2022, compared to Adjusted EBITDA of $(1.7
million), or $(0.13) per share basic and diluted for the fourth
quarter of 2021. Adjusted EBITDA, Adjusted EBITDA per share basic
and Adjusted EBITDA per share diluted are non-GAAP financial
measures, each of which are reconciled to the most directly
comparable financial measures calculated in accordance with GAAP
below under “Use of Non-GAAP Measures.”
- At December 31, 2022, Journey
Medical’s cash and cash equivalents totaled $32.0 million, compared
to $34.9 million on September 30, 2022, and $49.1 million at
December 31, 2021, a decrease of $2.9 million for the quarter and a
decrease of $17.1 million year-over-year.
Recent Corporate
Highlights:
- In March 2023, Journey Medical
announced completion of treatment in the Phase 1 clinical trial
assessing the impact of DFD-29 (Minocycline Modified Release
Capsules 40 mg) on the microbial flora of healthy adults. No
significant safety issues were noted during the study.
- In January 2023, Journey Medical
completed enrollment in its DFD-29 Phase 3 clinical program for the
treatment of papulopustular rosacea. Topline data from the two
DFD-29 Phase 3 clinical studies are expected to be announced in the
first half of 2023. Journey Medical plans to submit the NDA for
DFD-29 in the second half of 2023 and potential approval from the
U.S Food and Drug Administration ("FDA”) is anticipated in the
second half of 2024. In the Phase 2 clinical trials, DFD-29 (40mg)
demonstrated nearly double the efficacy when compared against
Oraycea® (European equivalent of Oracea®) on both co-primary
endpoints. For the first co-primary endpoint, Investigator’s Global
Assessment (“IGA”) treatment success, Oraycea only had a 33.33% IGA
treatment success rate, while DFD-29 achieved a 66.04% IGA
treatment success rate. For the second co-primary endpoint, the
change in total inflammatory lesion count, Oraycea only had a 10.5
reduction in inflammatory lesions, while DFD-29 achieved a 19.2
reduction in inflammatory lesions.
- In December 2022, Journey Medical
announced positive PK comparability data of DFD-29. The study
successfully demonstrated that the systemic exposure of DFD-29 (40
mg) was significantly lower than that of SOLODYN® (105 mg).
Additionally, the study showed that food did not have a significant
effect on the pharmacokinetics of DFD-29.
- In May 2022, Journey Medical
entered into three separate settlement agreements (the “Settlement
Agreements”) with Padagis for the patent infringement lawsuits that
the Company filed to enforce the patents covering Qbrexza, Amzeeq
and Zilxi. Pursuant to the terms of the Settlement Agreements,
Padagis is prohibited from launching generic versions of Qbrexza,
Amzeeq and Zilxi until August 15, 2030, July 1, 2031, and April 1,
2027, respectively. Subsequently, in December 2022, Journey Medical
entered into a settlement with Teva pharmaceuticals for a patent
infringement lawsuit filed by the Company related to the patents
covering Qbrexza.
- In January 2022, Journey Medical
received notice from its exclusive licensing partner in Japan,
Maruho Co., Ltd. (“Maruho”), that Japan’s Ministry of Health, Labor
and Welfare approved Rapifort® Wipes 2.5% (glycopyrronium tosylate
hydrate, Japanese equivalent of Qbrexza) for the treatment of
primary axillary hyperhidrosis. This approval triggered a milestone
payment of $10.0 million to Journey Medical, $7.5 million of which
was paid to Dermira, Inc. (“Dermira”) pursuant to the terms of the
Asset Purchase Agreement between Journey Medical and Dermira, with
net proceeds of $2.5 million paid to Journey Medical. Journey
Medical is entitled to receive royalties and commercial milestones
from Maruho’s sales of Rapifort, which was commercially launched in
May 2022.
- Also in January 2022, Journey
Medical acquired two FDA-approved topical minocycline products,
Amzeeq and Zilxi, and a Molecule Stabilizing Technology™ platform
from Vyne Therapeutics Inc. for an upfront payment of $20.0 million
and an additional $5.0 million, which were was paid on January 12,
2022 and on the one (1)-year anniversary of the closing,
respectively.
- Regarding the cybersecurity breach
that resulted in losses of $9.5 million in September 2021, the
federal government has been able to seize cryptocurrency assets
associated with the breach. Once the cryptocurrency has been
converted back into U.S. dollars, Journey Medical will receive a
notification letter to initiate the return of the cash to the
Company. The final amount and timing of return of funds is still
uncertain and yet to be determined.
Conference Call and Webcast
InformationJourney Medical management will conduct a
conference call and audio webcast on March 29, 2023, at 4:30 p.m.
ET.
To listen to the conference call, interested
parties within the U.S. should dial 1-866-777-2509 (domestic) or
1-412-317-5413 (international). All callers should dial in
approximately 10 minutes prior to the scheduled start time and ask
to be joined into the Journey Medical conference call. Participants
can register for the conference here:
https://dpregister.com/sreg/10175797/f5f355fdea. Please note that
registered participants will receive their dial-in number upon
registration.
A live audio webcast can be accessed on the News
and Events page of the Investors section of Journey Medical’s
website, www.journeymedicalcorp.com, and will remain available for
replay for approximately 30 days after the meeting.
About Journey Medical
CorporationJourney Medical Corporation (Nasdaq: DERM)
(“Journey Medical”) is focused on identifying, acquiring,
developing and strategically commercializing innovative,
differentiated dermatology products through its efficient sales and
marketing model. The company currently markets eight products that
help treat and heal common skin conditions. The Journey Medical
team comprises industry experts with extensive experience in
developing and commercializing some of dermatology’s most
successful prescription brands. Journey Medical is located in
Scottsdale, Arizona and was founded by Fortress Biotech, Inc.
(Nasdaq: FBIO). Journey Medical’s common stock is registered under
the Securities Exchange Act of 1934, as amended, and it files
periodic reports with the U.S. Securities and Exchange Commission
(“SEC”). For additional information about Journey Medical, visit
www.journeymedicalcorp.com.
Forward-Looking StatementsThis
press release may contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended. As used
below and throughout this press release, the words “the Company”,
“we”, “us” and “our” may refer to Journey Medical. Such statements
include, but are not limited to, any statements relating to our
growth strategy and product development programs and any other
statements that are not historical facts. The words “anticipate,”
“believe,” “estimate,” “may,” “expect,” “will,” “could,” “project,”
“intend” and similar expressions are generally intended to identify
forward-looking statements. Forward-looking statements are based on
management’s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating
results, financial condition and stock price. Factors that could
cause actual results to differ materially from those currently
anticipated include: risks relating to our growth strategy; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; risks relating to the
results of research and development activities; uncertainties
relating to preclinical and clinical testing; risks relating to the
timing of starting and completing clinical trials, including
disruptions that may result from hostilities in Europe; our
dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; potential recovery of funds lost from previously
disclosed cyber security breaches; as well as other risks described
in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form
10-K for the year ended December 31, 2022, subsequent Reports on
Form 10-Q, and our other filings we make with the SEC. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in our expectations or any changes in
events, conditions or circumstances on which any such statement is
based, except as may be required by law, and we claim the
protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of
1995.
Company Contact:Jaclyn Jaffe
(781) 652-4500ir@jmcderm.com
Media Relations Contact:Tony
Plohoros6 Degrees(908) 591-2839tplohoros@6degreespr.com
JOURNEY MEDICAL CORPORATION
Condensed Consolidated Balance Sheets($ in
thousands except for share and per share amounts)
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
2022 |
|
|
|
2021 |
|
|
ASSETS |
|
|
|
|
Current
assets |
|
|
|
|
Cash and cash equivalents |
$ |
32,003 |
|
|
$ |
49,081 |
|
|
Accounts receivable, net of reserves |
|
28,208 |
|
|
|
23,112 |
|
|
Inventory |
|
14,159 |
|
|
|
9,862 |
|
|
Prepaid expenses and other current assets |
|
3,309 |
|
|
|
2,438 |
|
|
Total
current assets |
|
77,679 |
|
|
|
84,493 |
|
|
|
|
|
|
|
Intangible assets, net |
|
27,197 |
|
|
|
12,552 |
|
|
Operating lease right-of-use asset, net |
|
189 |
|
|
|
89 |
|
|
Other assets |
|
95 |
|
|
|
150 |
|
|
Total assets |
$ |
105,160 |
|
|
$ |
97,284 |
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
Current
liabilities |
|
|
|
|
Accounts payable |
$ |
36,570 |
|
|
$ |
22,812 |
|
|
Due to related party |
|
413 |
|
|
|
641 |
|
|
Accrued expenses |
|
19,388 |
|
|
|
22,733 |
|
|
Accrued interest |
|
160 |
|
|
|
- |
|
|
Income taxes payable |
|
35 |
|
|
|
8 |
|
|
Line of credit |
|
2,948 |
|
|
|
812 |
|
|
Deferred cash payment (net of discount of $9) |
|
4,991 |
|
|
|
- |
|
|
Installment payments – licenses, short-term |
|
2,244 |
|
|
|
4,510 |
|
|
Operating lease liability, short-term |
|
83 |
|
|
|
98 |
|
|
Total
current liabilities |
|
66,832 |
|
|
|
51,614 |
|
|
|
|
|
|
|
Term loan
(net of debt discount of $180) |
|
19,826 |
|
|
|
- |
|
|
Installment
payments – licenses, long-term |
|
1,412 |
|
|
|
3,627 |
|
|
Operating
lease liability, long-term |
|
108 |
|
|
|
- |
|
|
Total liabilities |
|
88,178 |
|
|
|
55,241 |
|
|
|
|
|
|
|
Stockholders' equity |
|
|
|
|
Common stock, $.0001 par value, 50,000,000 shares authorized,
11,765,700 and 11,316,344 shares issued and outstanding as of
December 31, 2022 and December 31, 2021, respectively |
|
1 |
|
|
|
1 |
|
|
Common stock - Class A, $.0001 par value, 50,000,000 shares
authorized, 6,000,000 shares issued and outstanding as of December
31, 2022 and December 31, 2021 |
|
1 |
|
|
|
1 |
|
|
Additional paid-in capital |
|
85,482 |
|
|
|
80,915 |
|
|
Accumulated deficit |
|
(68,502 |
) |
|
|
(38,874 |
) |
|
Total stockholders' equity |
|
16,982 |
|
|
|
42,043 |
|
|
Total liabilities and stockholders' equity |
$ |
105,160 |
|
|
$ |
97,284 |
|
|
|
|
|
|
|
JOURNEY MEDICAL
CORPORATIONCondensed Consolidated Statements of
Operations($ in thousands except for share and per share
amounts)
|
|
Three-month
periods ended |
|
|
Twelve-month
periods ended |
|
|
|
December 31, |
|
|
December 31, |
|
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
Product revenue, net |
$ |
15,921 |
|
|
$ |
17,517 |
|
|
$ |
70,995 |
|
|
$ |
63,134 |
|
|
Other revenue |
|
45 |
|
|
|
- |
|
|
|
2,674 |
|
|
|
- |
|
|
Total
Revenue |
|
15,966 |
|
|
|
17,517 |
|
|
|
73,669 |
|
|
|
63,134 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods sold – product revenue |
|
7,718 |
|
|
|
9,525 |
|
|
|
30,775 |
|
|
|
32,084 |
|
|
Research and development |
|
4,256 |
|
|
|
1,992 |
|
|
|
10,943 |
|
|
|
2,739 |
|
|
Research and development - licenses acquired |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
13,819 |
|
|
Selling, general and administrative |
|
13,987 |
|
|
|
15,057 |
|
|
|
59,468 |
|
|
|
39,833 |
|
|
Wire transfer fraud loss |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
9,540 |
|
|
Total
operating expenses |
|
25,961 |
|
|
|
26,574 |
|
|
|
101,186 |
|
|
|
98,015 |
|
|
Loss from
operations |
|
(9,995 |
) |
|
|
(9,057 |
) |
|
|
(27,517 |
) |
|
|
(34,881 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other expense |
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
(50 |
) |
|
|
- |
|
|
|
(60 |
) |
|
|
(2 |
) |
|
Interest expense |
|
617 |
|
|
|
4,096 |
|
|
|
2,019 |
|
|
|
7,034 |
|
|
Foreign exchange transaction losses |
|
67 |
|
|
|
- |
|
|
|
89 |
|
|
|
- |
|
|
Change in fair value of derivative liability |
|
- |
|
|
|
263 |
|
|
|
- |
|
|
|
447 |
|
|
Total other
expense |
|
634 |
|
|
|
4,359 |
|
|
|
2,048 |
|
|
|
7,479 |
|
|
Loss
before income taxes |
|
(10,629 |
) |
|
|
(13,416 |
) |
|
|
(29,565 |
) |
|
|
(42,360 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax
expense |
|
13 |
|
|
|
8,335 |
|
|
|
63 |
|
|
|
1,634 |
|
|
Net
Loss |
$ |
(10,642 |
) |
|
$ |
(21,751 |
) |
|
$ |
(29,628 |
) |
|
$ |
(43,994 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per
common share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
$ |
(0.60 |
) |
|
$ |
(1.64 |
) |
|
$ |
(1.69 |
) |
|
$ |
(4.32 |
) |
|
Weighted
average number of common shares: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
17,729,238 |
|
|
|
13,244,773 |
|
|
|
17,531,274 |
|
|
|
10,189,844 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Use of Non-GAAP Measures:
In addition to the GAAP financial measures as
presented in our Form 10-K that will be filed with the Securities
and Exchange Commission (“SEC”), the Company has, in this press
release, included certain non-GAAP measurements, including Adjusted
EBITDA, Adjusted EBITDA per share basic and Adjusted EBITDA per
share diluted. We define Adjusted EBITDA as net income (loss)
excluding interest, taxes and depreciation, less certain other
non-cash and infrequent items not considered to be normal,
recurring operating expenses, including, share-based compensation
expense, amortization of acquired intangible assets, inventory
step-ups from the purchases of intangibles assets and products,
severance, wire transfer fraud loss and foreign exchange
transaction losses. In particular, we exclude the following matters
for the reasons more fully described below:
- Share-Based
Compensation Expense: We exclude share-based compensation
from our adjusted financial results because share-based
compensation expense, which is non-cash, fluctuates from period to
period based on factors that are not within our control, such as
our stock price on the dates share-based grants are issued.
- Non-core and
Short-term Research and Development Expense: We exclude
research and development costs incurred in connection with our
DFD-29 product candidate, which is the only product in our
portfolio not currently approved for marketing and sale, because we
do not consider such costs to be normal, recurring operating
expenses that are core to our long-term strategy. Instead, our
long-term strategy is focused on the marketing and sale of our core
of licensed and FDA-approved dermatological products.
- Amortization of
Acquired Intangible assets: We exclude the impact of certain
amounts recorded in connection with the acquisitions of intangible
assets that are either non-cash or not normal, recurring operating
expenses due to their nature, variability of amounts, and lack of
predictability as to occurrence and/or timing. These amounts may
include non-cash items such as the amortization of acquired
intangible assets and amortization of step-ups of acquisition
accounting adjustments to inventories.
Adjusted EBITDA per share basic and Adjusted
EBITDA per share diluted are determined by dividing the resulting
Adjusted EBITDA by the number of shares outstanding on an actual
and fully diluted basis.
Management believes use of these non-GAAP
measures provide meaningful supplemental information regarding the
Company’s performance because (i) it allows for greater
transparency with respect to key measures used by management in its
financial and operational decision-making, (ii) it excludes the
impact of non-cash or, when specified, non-recurring items that are
not directly attributable to the Company’s core operating
performance and that may obscure trends in the Company’s core
operating performance and (iii) it is used by institutional
investors and the analyst community to help analyze the Company's
results. However, Adjusted EBITDA, Adjusted EBITDA per share basic,
Adjusted EBITDA per share diluted and any other non-GAAP financial
measures should be considered as a supplement to, and not as a
substitute for, or superior to, the corresponding measures
calculated in accordance with GAAP. Further, non-GAAP financial
measures used by the Company and the manner in which they are
calculated may differ from the non-GAAP financial measures or the
calculations of the same non-GAAP financial measures used by other
companies, including the Company’s competitors.
The table below provides a reconciliation from
GAAP to non-GAAP measures:
JOURNEY MEDICAL CORPORATION
Reconciliation of GAAP to Non-GAAP Adjusted EBITDA
(Adjusted Operating Net Loss)(Dollars in thousands except
for share and per share amounts)
|
|
Three-month periods ended |
|
Twelve-month
periods Ended |
|
|
|
December 31, |
|
December 31, |
|
|
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
|
GAAP Net Loss |
|
$ |
(10,642 |
) |
|
$ |
(21,751 |
) |
|
$ |
(29,628 |
) |
|
$ |
(43,994 |
) |
|
|
|
|
|
|
|
|
|
|
|
EBITDA: |
|
|
|
|
|
|
|
|
|
Interest |
|
|
567 |
|
|
|
4,096 |
|
|
|
1,959 |
|
|
|
7,032 |
|
|
Taxes |
|
|
13 |
|
|
|
8,335 |
|
|
|
63 |
|
|
|
1,634 |
|
|
Depreciation |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
Amortization of acquired intangible assets |
|
|
1,227 |
|
|
|
491 |
|
|
|
4,277 |
|
|
|
2,474 |
|
|
EBITDA |
|
|
(8,835 |
) |
|
|
(8,829 |
) |
|
|
(23,329 |
) |
|
|
(32,854 |
) |
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP Adjusted EBITDA: |
|
|
|
|
|
|
|
|
|
Share-based compensation |
|
|
1,440 |
|
|
|
2,425 |
|
|
|
4,425 |
|
|
|
2,466 |
|
|
Change in
fair value of derivative liabilities |
|
|
- |
|
|
|
263 |
|
|
|
- |
|
|
|
447 |
|
|
Inventory
step-up expense |
|
|
110 |
|
|
|
2,299 |
|
|
|
635 |
|
|
|
6,538 |
|
|
Wire
transfer fraud loss |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
9,540 |
|
|
R&D |
|
|
4,217 |
|
|
|
1,992 |
|
|
|
10,870 |
|
|
|
2,739 |
|
|
Foreign exchange transaction losses |
|
|
67 |
|
|
|
- |
|
|
|
89 |
|
|
|
- |
|
|
Severance |
|
|
- |
|
|
|
175 |
|
|
|
27 |
|
|
|
175 |
|
|
Non-GAAP Adjusted EBITDA |
|
$ |
(3,001 |
) |
|
$ |
(1,675 |
) |
|
$ |
(7,283 |
) |
|
$ |
(10,949 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss per common share Basic and diluted: |
|
|
|
|
|
|
|
|
|
GAAP Net
loss |
|
$ |
(0.60 |
) |
|
$ |
(1.64 |
) |
|
$ |
(1.69 |
) |
|
$ |
(4.32 |
) |
|
Non-GAAP
Net loss |
|
$ |
(0.17 |
) |
|
$ |
(0.13 |
) |
|
$ |
(0.42 |
) |
|
$ |
(1.07 |
) |
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of common shares Basic and diluted: |
|
|
17,729,238 |
|
|
|
13,244,773 |
|
|
|
17,531,274 |
|
|
|
10,189,844 |
|
|
|
|
|
|
|
|
|
|
|
|
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jul 2023 to Jul 2024